Creating Value by Overcoming Treatment Barriers View previous quarters - Today Latest News View all press releases 05.06.26 Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET Read More 03.30.26 Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film Read More 03.20.26 Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer Read More Events View all events Upcoming Events 05.14.26 8:00 AM EDT Q1 2026 Aquestive Therapeutics, Inc. Earnings Conference Call Past Events 03.10.26 8:25 AM EDT Citizens Life Sciences Conference 03.09.26 10:40 AM EDT Leerink Partners Global Healthcare Conference 2026 Presentations View all presentations Corporate Presentation – February 2026 Anaphylm™ (dibutepinephrine) Sublingual Film Complete Response Letter Supplemental Material 1.1 MB Anaphylm Pre-NDA Meeting Supplemental Material 525.4 KB
05.06.26 Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET Read More
03.30.26 Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film Read More
03.20.26 Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer Read More
